Literature DB >> 8220363

The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life.

M A Sprangers1, A Cull, K Bjordal, M Groenvold, N K Aaronson.   

Abstract

The EORTC Study Group on Quality of Life (the Study Group) has adopted a modular approach to quality of life (QOL) assessment in cancer clinical trials. A 'core' instrument-the QLQ-C30-has been designed to cover a range of QOL issues relevant to a broad spectrum of cancer patients. It is intended that this QLQ-C30 be supplemented by more specific subscales ('modules') to assess aspects of QOL of particular importance to specific subgroups of patients. Since individual members of the Study Group were to be involved in module development, guidelines were required to standardize the module development process in order to ensure uniformly high quality across modules. These guidelines are presented in this paper. The term 'module' is defined, the composition of modules is outlined, and the criteria used to develop modules are specified. The module development process, consisting of four phases (generation of relevant QOL issues, operationalization of the QOL issues into a set of items, pretesting the module questionnaire, and large-scale field-testing) is described in detail. Further, issues related to cross-cultural instrument development, and the need for monitoring the module development process from within the Study Group are discussed. Finally, experiences with developing two site-specific modules (i.e., for head and neck, and breast cancer), are presented and the extent to which the guidelines meet practical requirements is discussed. The guidelines appear to provide a practical tool for module construction, that can facilitate the development of a comprehensive system for assessing the QOL of cancer patients internationally.

Entities:  

Mesh:

Year:  1993        PMID: 8220363     DOI: 10.1007/bf00434800

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  15 in total

1.  Measuring impact of sickness in patients with nonspecific abdominal complaints in a Dutch family practice setting.

Authors:  H M Jacobs; A Luttik; F W Touw-Otten; M Kastein; R A de Melker
Journal:  Med Care       Date:  1992-03       Impact factor: 2.983

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  Spanish version of the Nottingham Health Profile: translation and preliminary validity.

Authors:  J Alonso; J M Anto; C Moreno
Journal:  Am J Public Health       Date:  1990-06       Impact factor: 9.308

4.  A modular approach to quality-of-life assessment in cancer clinical trials.

Authors:  N K Aaronson; M Bullinger; S Ahmedzai
Journal:  Recent Results Cancer Res       Date:  1988

5.  Pitfalls in measuring the health status of Mexican Americans: comparative validity of the English and Spanish Sickness Impact Profile.

Authors:  R A Deyo
Journal:  Am J Public Health       Date:  1984-06       Impact factor: 9.308

6.  The Nottingham Health Profile: subjective health status and medical consultations.

Authors:  S M Hunt; S P McKenna; J McEwen; J Williams; E Papp
Journal:  Soc Sci Med A       Date:  1981-05

7.  A cross-cultural comparison of health status values.

Authors:  D L Patrick; Y Sittampalam; S M Somerville; W B Carter; M Bergner
Journal:  Am J Public Health       Date:  1985-12       Impact factor: 9.308

8.  A Chicano version of the Sickness Impact Profile (SIP). A health care evaluation instrument crosses the linguistic barrier.

Authors:  B S Gilson; D Erickson; C T Chavez; R A Bobbitt; M Bergner; W B Carter
Journal:  Cult Med Psychiatry       Date:  1980-06

9.  Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.

Authors:  H Schipper; J Clinch; A McMurray; M Levitt
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

10.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

View more
  111 in total

1.  The EORTC breast cancer-specific quality of life questionnaire (EORTC QLQ-BR23): translation and validation study of the Iranian version.

Authors:  A Montazeri; I Harirchi; M Vahdani; F Khaleghi; S Jarvandi; M Ebrahimi; M Haji-Mahmoodi
Journal:  Qual Life Res       Date:  2000-03       Impact factor: 4.147

Review 2.  A review of the progress towards developing health-related quality-of-life instruments for international clinical studies and outcomes research.

Authors:  R T Anderson; N K Aaronson; M Bullinger; W L McBee
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

3.  Quality of Life after Autologous Peripheral Blood Stem Cell Transplantation and High-Dose Chemotherapy in High-Risk Breast Cancer Patients.

Authors:  Li Zhang; Zhongsheng Tong; Shufen Li; Xiubao Ren; Baozhu Ren; Xu Wang; Shui Cao; Chen Wang; Lihong He
Journal:  Breast Care (Basel)       Date:  2009-12-28       Impact factor: 2.860

4.  Pancreaticoduodenectomy with vascular resection for local advanced pancreatic head cancer: a single center retrospective study.

Authors:  Chunyou Wang; Heshui Wu; Jiongxin Xiong; Feng Zhou; Jing Tao; Tao Liu; Gang Zhao; Shanmiao Gou
Journal:  J Gastrointest Surg       Date:  2008-08-06       Impact factor: 3.452

5.  Evaluating patients for psychosocial distress and supportive care needs based on health-related quality of life in primary brain tumors: a prospective multicenter analysis of patients with gliomas in an outpatient setting.

Authors:  Anne-Katrin Hickmann; Marlene Hechtner; Minou Nadji-Ohl; Mareile Janko; Ann Katrin Reuter; Karoline Kohlmann; Markus Haug; Sonja Grüninger; Monika Deininger; Oliver Ganslandt; Jochem König; Christian Rainer Wirtz; Jan Coburger; Mirjam Renovanz
Journal:  J Neurooncol       Date:  2016-09-16       Impact factor: 4.130

6.  The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires.

Authors:  D Osoba; N K Aaronson; M Muller; K Sneeuw; M A Hsu; W K Yung; M Brada; E Newlands
Journal:  Qual Life Res       Date:  1996-02       Impact factor: 4.147

7.  The PedsQL in pediatric patients with Spinal Muscular Atrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Generic Core Scales and Neuromuscular Module.

Authors:  Susan T Iannaccone; Linda S Hynan; Anne Morton; Renee Buchanan; Christine A Limbers; James W Varni
Journal:  Neuromuscul Disord       Date:  2009-10-28       Impact factor: 4.296

8.  Assessment of body image in patients undergoing surgery for colorectal cancer.

Authors:  Robert N Whistance; Rebecca Gilbert; Peter Fayers; Robert J Longman; Anne Pullyblank; Michael Thomas; Jane M Blazeby
Journal:  Int J Colorectal Dis       Date:  2009-12-02       Impact factor: 2.571

9.  The PedsQL in pediatric asthma: reliability and validity of the Pediatric Quality of Life Inventory generic core scales and asthma module.

Authors:  James W Varni; Tasha M Burwinkle; Michael A Rapoff; Jodi L Kamps; Nancy Olson
Journal:  J Behav Med       Date:  2004-06

10.  Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer.

Authors:  Arti Hurria; Enrique Soto-Perez-de-Celis; Jacob B Allred; Harvey Jay Cohen; Anait Arsenyan; Karla Ballman; Jennifer Le-Rademacher; Aminah Jatoi; Julie Filo; Jeanne Mandelblatt; Jacqueline M Lafky; Gretchen Kimmick; Heidi D Klepin; Rachel A Freedman; Harold Burstein; Julie Gralow; Antonio C Wolff; Gustav Magrinat; Myra Barginear; Hyman Muss
Journal:  J Am Geriatr Soc       Date:  2018-08-26       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.